Quarterly Result1 Aug 2026, 05:10 pm
SMS Pharma Q1 FY27 Revenue Up 6% YoY to ₹207 Cr
AI Summary
SMS Pharmaceuticals Ltd reported unaudited financial results for the quarter ended June 30, 2026. Revenue from operations increased by 6% year-on-year to ₹207.0 crore, driven by broad-based growth in high-value APIs. Gross margin remained strong above 45%, and EBITDA margin was sustained at approximately 20%. Profit After Tax (PAT) saw an 8% YoY increase. The company completed 4 DMF/CEP filings and is on track to meet its FY27 target. A ₹280 crore capex program is progressing as planned, and the company approved an infusion of up to ₹50 crore as a loan into its subsidiary, SMS Peptides Private Limited. The R&D team strength increased to 200.
Key Highlights
- Revenue grew 6% YoY to ₹207 Cr, driven by high-value APIs.
- Gross margin exceeded 45%, with EBITDA margin sustained around 20%.
- PAT increased 8% YoY; 4 DMF/CEP filings completed.
- ₹50 Cr loan approved for subsidiary SMS Peptides.
- ₹280 Cr capex program progressing, expected completion by FY27.
Price Impact
More from SMSPHARMA